Anaemia impacts significantly on quality of life and appears markedly to limit disease control. Erythropoietin stimulates erythrocyte formation and the human recombinant form is useful in treating anaemia in cancer patients. Over the past decade erythropoietin has been associated with amelioration of anaemia and reduced need for blood transfusions. Nevertheless, several pre-clinical and clinical trials, employing relatively high doses of erythropoietin, have been halted recently following increased mortality and morbidity, primarily due to thrombotic events and possible tumour growth stimulation. It is, therefore, too early to know whether erythropoietin is useful in controlling morbidity and mortality in cancer-related anaemia. The risk-benefit of erythropoietic agents should be studied in carefully controlled trials. This review discusses prevalent issues and addresses key questions concerning the use of erythropoietic agents for the treatment of cancer-related anaemia.
Introduction
Cancer-related anaemia is a common haematological disorder in patients with cancer, especially in the advanced stages, occurring in 10 -40% of cancer cases, depending upon the tumour type and chemotherapy used. 1 It appears to result from a range of factors, including chronic inflammation, blood loss, nutritional deficiencies, haemolysis, bone marrow infiltration by malignant cells, low serum erythropoietin (EPO) levels, and a decrease in bone marrow responsiveness to EPO. Anaemia is a well-recognized negative prognostic factor for cancer patients treated with radiotherapy and chemotherapy. 2 -4 Severe chemotherapy-induced anaemia significantly impairs quality of life, with fatigue and weakness reducing the patient's capacity for activity. The consequences of anaemia, therefore, can adversely affect patients' quality of life and may even alter their response to cancer treatments.
Blood transfusions have been the mainstay of treatment for cancer-related anaemia; however, associated risks of transfusion-related reactions and transmission of infection can involve X Guan, L Chen Erythropoietin in cancer-related anaemia numerous other hazards and complications. 5 For this reason, EPO has been proposed as an alternative to blood transfusions, to increase haemoglobin levels and to improve quality of life by decreasing fatigue. Recombinant EPO (rEPO), a recombinant form of human erythropoietin (rHuEPO), is currently used in cancer patients to prevent or limit anaemia secondary to chemotherapy. By increasing haemoglobin and haematocrit levels, rHuEPO has been shown to reduce the need for blood transfusions in patients with haematological malignancies. Considering the detrimental effects that anaemia can have on cancer patients' physical and emotional well-being and therapeutic outcomes, rHuEPO therapy has the potential to provide substantial clinical benefits.
Although EPO has been shown to be effective in the treatment of anaemia in cancer patients, 6 one recent randomized, double-blind, placebo-controlled trial has reported that, although epoetin-β corrects anaemia, it does not appear to improve cancer control or survival. 7 In this present review, by reference to a large number of clinical trials, we outline the risks and benefits of EPO in the treatment of cancerrelated anaemia and go on to propose some strategies for these treatments. It should be noted, however, that the exact role of EPO in the treatment of cancer-related anaemia and the underlying mechanisms involved remain to be thoroughly evaluated.
Benefits of EPO treatments
Erythropoietic agents are widely believed to have both objective and subjective benefits: rHuEPO has been demonstrated to ameliorate anaemia associated with cancer and EPO effectively increases haemoglobin levels and reduces the need for emergency blood transfusions. EPO is effective for the treatment of tumour-induced anaemia and the prevention and correction of chemotherapy-and radiotherapy-induced anaemia and modality. 8 Dozens of clinical trials, in diverse groups of cancer patients, have convincingly demonstrated the power of EPO to increase haemoglobin levels and to reduce the need for potentially risky red blood cell transfusions. 9 In addition, several studies have highlighted the beneficial role of EPO in clinical outcomes, many trials suggesting that EPO can improve patients' quality of life, tumour response to therapy and overall survival. 10 -13 
ANAEMIA AMELIORATION AND BLOOD TRANSFUSION REDUCTION
Anaemia is associated with a low quality of life as well as poor treatment outcome. EPO improves the quality of life for anaemic patients with cancer and restores their ability to perform normal daily activities. The benefit of treatment with rHuEPO is not just limited to the symptomatology of anaemia, it also provides an alternative to blood transfusions. It is known that transfusions have a potential risk of infection and their high cost must also be taken into account. A recent meta-analysis of five randomized, placebocontrolled trials strongly suggests that early treatment with epoetin-α may significantly optimize clinical benefits by reducing the necessity for blood transfusions in cancer patients receiving chemotherapy. 14 -16 rHuEPO is a considerably improved treatment for anaemic cancer patients, increasing haemoglobin serum levels and reducing the need for blood transfusions, thereby improving their quality of life.
TUMOUR HYPOXIA AND ENHANCED THERAPEUTIC EFFICACY
Acute or chronic anaemia is often associated with the development of tumour hypoxia, a condition where tumour cells in the hypoxic X Guan, L Chen Erythropoietin in cancer-related anaemia areas of solid tumours are resistant to conventional chemotherapy and radiotherapy. 17 Tumour hypoxia adversely impacts radiotherapy or combined radiotherapy-chemotherapy outcomes 18 and chronic hypoxia, caused by anaemia, decreases the efficacy of chemotherapy as well as radiotherapy. Tumour response to radiation therapy, however, appears to be enhanced by an EPO-induced haemoglobulin increase. The therapeutic potential of EPO has, therefore, gained increased popularity among radiation oncologists because patients with a high blood haemoglobin level following radiotherapy have an improved prognosis. Debate on how haemoglobin affects radiotherapy outcomes in this way is still continuing. Prevention and amelioration of chemotherapy-and radiotherapy-induced anaemia is, therefore, a major goal of modern oncotherapy.
IMMUNOLOGICAL FUNCTION IMPROVEMENT
Recent research shows that rHuEPO treatment boosts the immune system, being associated with effects on a variety of immunological parameters and functions. It may also have an anti-myeloma function, affecting disease progression and improving prognosis in the early stages of multiple myeloma, before anaemia develops. 19 It can, therefore, be concluded that EPO treatment may be associated with improved immunological function.
Potential risks from EPO treatment
Anaemia is associated with poor cancer control, particularly in patients undergoing radiotherapy. Anaemia correction with epoetin-β, however, has been shown not to improve the outcome of radiotherapy among patients with head and neck cancer. 7 The Breast Cancer Erythropoietin Trial (BEST) examined EPO treatment in nonanaemic metastatic breast cancer patients but was terminated early when a higher mortality rate was observed in the EPO treatment group. 20 This observation has raised valid concern about the precise role of EPO in cancer-related anaemia, but little attention has been given to possible biological explanations and the potential underlying mechanisms are largely still unknown.
EPO RECEPTOR EXPRESSION IN TUMOUR CELLS
EPO was the first known haematopoietic growth factor and is well known for its role in the control of erythropoiesis; it acts by binding to its cognate receptor on the surface of erythroid progenitor cells. In human erythroid progenitors, EPO stimulation enhances the levels of cyclins D1 and D3, and can mediate proliferation of primary human erythroid progenitors by p27 Kip1 downregulation and stimulation of its degradation by E3 ligase. 21 The question is whether EPO stimulates proliferation of tumour cells? The expression of both EPO and its EPO receptor (EPO-R) has been recognized in a variety of human cancers, including breast, prostate, colon, ovary, uterine, cervical, glioblastoma, and head and neck squamous cell carcinoma. 22 EPO-R is also expressed in cells of both the melanocytic lineage 23 and non-small-cell lung carcinomas. 24 In vitro and animal models have shown EPO-R mRNA and/or protein may be present in a range of human tumours and cancer cell lines. 25 The expression of EPO-R is upregulated in response to hypoxia and EPO stimulation in melanoma cells, and EPO appears to X Guan, L Chen Erythropoietin in cancer-related anaemia promote melanoma cell survival by activating an Akt-dependent signalling pathway. 26 Furthermore, a number of preclinical studies have demonstrated EPOmediated activation of the mitogenactivated protein kinase (MAPK), Janus kinase-signal transducer and activator of transcription (JAK-STAT), and nuclear factor κB (NFκB) signalling pathways in a variety of human cancers. 27 EPO not only stimulates cancer cell proliferation and inhibits apoptosis, 22, 28, 29 but also stimulates migration and invasion of cancer cells. 30 -32 A complete understanding of EPO-R function in tumour cells remains absent from the current literature.
What is certain is that, in red blood cells, EPO is a key component of differentiation. Erythropoiesis-stimulating agents have been reported to have tumour cell growthmodulating effects. There is also a need for more clinical trials to be carried out for a further assessment of the effects of EPO on tumours and cancer treatments (i.e. EPO might adversely affect the prognosis of head and neck cancer patients if these cancer cells express EPO-Rs). With regards to EPO-R negative cancers, epoetin-β does not appear to affect the clinical course of patients. 33 A possible explanation is that stimulation with rHuEPO protects a residual tumour from radiation treatment. Further research should be performed to elucidate fully the molecular mechanisms behind this action.
RISK OF THROMBOEMBOLIC EVENTS
According to an updated meta-analysis based on a systematic review of 57 trials and 9353 cancer patients, treatment with epoetin or darbepoetin increased the risk of thromboembolic events. Uncertainties remain as to whether and how epoetin or darbepoetin affect overall patient survival. 34 
INADEQUATE EPO RESPONSE TO ANAEMIA
Some chemotherapeutic agents, such as platinum or 5-fluorouracil, slightly lower haemoglobin levels but do not depress EPO production. 35 An increase in EPO levels has been observed following courses of 5-fluorouracil-or platinum-based chemotherapy. 35 Cancer-related anaemia is associated with an inadequate EPO response to anaemia. Thus, it would appear that it is not the endogenous EPO concentration but, rather, the EPO response to anaemia that should be evaluated as a valid parameter in patients with solid tumours.
Strategies for EPO treatments
Further clinical studies are required for the assessment of indications, for the identification of optimal administration modalities, and for cost-analysis of the potentially promising use of EPO therapy in cancer patients. Possible strategies to optimize EPO management are discussed in the following sections.
DEVELOPMENT OF EVIDENCE-BASED GUIDELINES
We recommend updating the standards, options and recommendations for clinical practice guidelines to include the use of rHuEPO in the management of anaemia in oncology. The guidelines should take into account critical appraisal of the best and most recently available evidence, along with expert opinions. The clinical situations in which the administration of rHuEPO is indicated and those in which it is not indicated (except in the setting of randomized, controlled trials) should also be taken into consideration. Evidence-based guidelines must be updated and refined X Guan, L Chen Erythropoietin in cancer-related anaemia according to the full body of data currently available. 36 For example, it is recommended that rHuEPO is administered when a patient's haemoglobin level is at risk of falling below 8 g/dl and that treatment is maintained until levels rise above 13 g/dl. The role of rHuEPO is clear when the haemoglobin concentration is < 10 g/dl, but is still unclear when the concentration is between 10 and 12 g/dl. When the haemoglobin concentration is between 12 and 14 g/dl, there is no justification for the use of rHuEPO to prevent anaemia, except in the setting of autologous blood transfusion programmes prior to major surgery. Anti-anaemic treatment is not justified if the haemoglobin concentration is > 14 g/dl, except in the setting of a randomized clinical trial. 37 Evidence-based medicine offers the opportunity to use medical evidence to reduce uncertainty. It combines clinical judgement and experience, the finest available scientific evidence and patient preferences to improve medical decisionmaking. Guidelines for the stimulation of EPO in patients with malignancies should be studied in carefully controlled trials.
FINDING MORE SIGNIFICANT BASELINE PREDICTORS
Recently, other significant predictors of EPO application have been identified, in addition to baseline haemoglobin levels. Katodritou et al. 38 suggested that a combination of the soluble transferrin receptor/log ferritin (sTfR-F) index and hypochromic erythrocytes (HYPO%) in a diagnostic plot could be used as a predictive model to help identify those patients who would benefit from rHuEPO therapy. Evaluation of the sTfR-F index and HYPO% as potential predictors of response to rHuEPO in anaemic patients with multiple myelomas should occur before and in the early course of treatment. This approach would also aid in identifying functional iron deficiencies that require iron supplementation, before and in the early course of treatment, thus contributing to optimization of rHuEPO therapy. Iron status can now be precisely characterized with relative ease by determining serum ferritin, transferrin saturation and, if necessary, HYPO% and the haemoglobin content of erythrocytes.
OPTIMIZING INDIVIDUAL DOSE AND FREQUENCY
In August 2004, the US Food and Drug Administration's MedWatch Safety Information
Program announced recommendations stating that target haemoglobin levels in patients with cancer should be individually determined, 39 and that several new treatment options would soon become available clinically. 40 Scientific advances in drug development have resulted in the development of potential novel agents and new strategies for stimulating erythropoiesis. Advances are of possible benefit in treating anaemia due to various causes. A randomized comparison of darbepoetin-α administered twice-weekly and epoetin-α administered weekly for chemotherapy-induced anaemia was undertaken recently by the 20030125 Study Group, the analysis showing that less frequent dosing offers more potential benefits for patients, caregivers and healthcare providers. 41 A randomized, double-blind, placebo-controlled study involving the administration of epoetin-α once a week, augmented the erythropoietic response in critically ill patients, as indicated by increased EPO levels and other haematological variables (percentage reticulocytes [0-T last ]) in treated patients. 42 Androgen (nandrolone decanoate) was used as an adjuvant for EPO dose reduction in the X Guan, L Chen Erythropoietin in cancer-related anaemia treatment of anaemia in patients on haemodialysis. 43 Furthermore, treatment with EPO alone or in combination with granulocyte colony-stimulating factor may significantly improve anaemia. 44
Conclusions
Elucidation of the role of EPO in normal cellular functions and tumour progression will improve our ability to use EPO rationally in the clinical setting. Assessment of the risk-benefit ratio of EPO treatment in cancerrelated anaemia should be studied in carefully controlled trials. Well-controlled studies in vitro and in xenograft models are necessary to define the contribution of EPO to tumour growth, apoptosis, angiogenesis, and to chemotherapy and radiotherapy sensitivity for different types of cancer. The contribution of the EPO/EPO-R signalling axis to cancer progression is not completely straightforward, as the influence of EPO/EPO-R on different cancer types appears to be quite variable. Recognition of the EPO/EPO-R signalling mechanisms within cancer cells may redefine our present understanding of anaemia in cancer patients. EPO/EPO-R signalling results in varied effects for different types cells, both healthy and cancerous. As the role of EPO/EPO-R in cancer cells continues to be investigated, serious deliberation is required with regards to current clinical guidelines for the use of rHuEPO in cancer patients. With respect to potential risks and benefits, EPO treatment should doubtless continue in cancer patients with strict monitoring of haemoglobin levels.
